Please type a plus sign (+) inside this box → PTO/SB/08A (10-96)
Approved for use through 10/31/99. OMB 0651-0031
Patent and Trademark Office U.S. DEPARTMENT OF CEMMERCE Under the Paperwork Reduction Act of 1995, no persons are required to resp Substitute for form 1449A/PTO INFORMATION DISCLOSURE STATEMENT BY APPLICANT (use as many sheets as necessary)

of

2

1

Sheet

cond to a collection of information unle	ess it contains a valid OMB con-	for Aun	nber.
	lete if Known	至	S
Application Number	09/807,332	R	m
Filing Date	April 11, 2001		-
First Named Inventor	Thomas G. Burk		-50
Group Art Unit		- 30 -	-1
Examiner Name		<u>5</u>	7
Attomey Docket Number	434-204	8	

			U.S. PATENT DOCI	UMENTS	<u></u>
Examiner nitials*	Cite No.1	U.S. Patent Document Kind Code ² (if known)	Name of Patenton as Applicant	Date of Publication of Cited Document MM-DD-YYYY	Pages, Solumns, Lines, Where Relevant Passages or Relevant
0	1	5,552,156	Burke	09/03/1996	Figures Appear
1	2	5,736,156 5,726,181	Burke Hausheer et al.	04/07/1998 03/10/1998	
	5	5,714,170 5,677,286	Baserga et al. Shull et al.	02/03/1998 10/14/1997	
11	6	5,674,873 5,651,986	Hausheer et al. Brem et al.	10/14/1997 10/07/1997 07/29/1997	
++	8	5,604,233 5,583,034	Hausheer et al.	02/18/1997	
V	10	5,447,936	Green et al. Hausheer et al.	12/10/1996 09/05/1995	
	11	5,276,019	Cohen et al.	01/04/1994	/
	_				
	\dashv				
_	_				

	FOREIGN PATENT DOCUMENTS							
Examiner Cite	Cite		Foreign Patent Document			Date of Publication of	Pages, Columns, Lines,	\top
Initials*	No.1	Office ³	Number ⁴	Kind Code ⁵ (if known)	Name of Patentee or Applicant of Cited Document	Cited Document MM-DD-YYYY	Where Relevant Passages or Relevant Figures Appear	T6
								\top
								+
			_					╁
								┼
						 		₩
						 		₩
								
		_						

Examiner Signature	Dav	Date Considered Cludo	-
SEVANDALED A SILVE			

Burden Hour Statement: This form is estimated to take 2.0 hours to complete. Time will vary depending upon the needs of the individual case. Any comments on the amount of time you are required to complete this form should be sent to the Chief Information Officer, Patent and Trademark Office, Washington, DC 20231. DO NOT SEND FEES OR COMPLETED FORMS TO THIS ADDRESS. SEND TO: Assistant Commissioner for Patents, Washington, DC 20231.

EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.

¹ Unique citation designation number. ² See attached Kinds of U.S. Patent Documents. ³ Enter Office that issued the document, by the two-letter code (WIPO Standard ST.3). ⁴ For Japanese patent documents, the indication of the year of the reign of the Emperor must precede the serial number of the patent document. ⁵ Kind of document by the appropriate symbols as indicated on the document under WIPO Standard ST. 16 if possible. ⁶ Applicant is to place a check mark here if English language Translation is attached.

_	Į	J
Γ	T	1
)
Γ	T	1
<	-	7
Γ	T	Ì
	_	7

Please type a plus sign (+) inside this box -> PTO/SB/08B (10-96)
Approved for use through 10/31/99. OMB 0651-0031
Patent and Trademark Office: U.S. DEPARTMENT OF COMMERCE Ander the Paperwork Reduction Act of 1995, no persons are required to respond to a collection of information unless it contains a valid OMB control number. Substitute for form 1449B/PTO Complete if Known INFORMATION DISCLOSURE **Application Number** Filing Date STATEMENT BY APPLICANT First Named Inventor

(use as many sheets as necessary)

of

Sheet

09/807,332 April 11, 2001 Thomas G. Burke Group Art Unit **Examiner Name** Attorney Docket Number 434-204

		OTHER PRIOR ART. MON PATENTS I	8
	$\overline{}$	OTHER PRIOR ART NON PATENT LITERATURE DOCUMENTS	C
Examiner Initials*	Cite No. ¹	item (book, magazine, journal, serial, symposium, catalog, etc.), date, page(s), volume-issue number(s), publisher, city and/or country where published.	1
P^	1	JAXEL et al., Effect of Local DNA sequence on Topoisomerase I Cleavage in the Presence or Absence of Camptothecin. The Journal of Biological Chemistry. 25 October 1991, Vol. 266, No. 30, pages 20418-20423, especially the abstract.	
	2	mechanism in DNA-topoisomerase I as a target of antitumor driver option.	
	3	approach. Spectrosc. Biol. Mol.: Mod. Trends. 1997, Eur. Conf. 7th, Conference Abstet. LETEURTRE et al. Specific Interaction of Camptothecin, a Topoisomerase I Inhibitor, with Guanine Residues of DNA detected by Photoactivation at 365 nm. Biochemistry.	\dagger
	4	1993. Vol. 32, pages 8955-8962, especially abstract. GIOVANELLA, et al., DNA Topoisomerase I-Targeted Chemotherapy of Human Colon Cancer in Xenografts, Science 246: 1046-1048 (Washington, DC) (1989)	\dagger
V	ا د	MADDEN, T.D., BURKE, T.G., REDELMEIER, T.E. and BALLY, M.B., "Encapsulation of Topotecan in Lipid-Based Carriers: Evaluation of Drug Stability and Plasma Elimination in a Murine Model", Proc. Am. Soc. Clin. Oncol., 17: 196a (1998)	
		1	
		·	
_	+		

Examiner Signature	Dalm	Date Considered	Wirlor

Burden Hour Statement: This form is estimated to take 2.0 hours to complete. Time will vary depending upon the needs of the individual case. Any comments on the amount of time you are required to complete this form should be sent to the Chief Information Officer, Patent and Trademark Office, Washington, DC 20231. DO NOT SEND FEES OR COMPLETED FORMS TO THIS ADDRESS. SEND TO: Assistant Commissioner for Patents, Washington, DC 20231.



^{*}EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.

¹ Unique citation designation number. ² Applicant is to place a check mark here if English language Translation is attached.